References
- Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow up. Br. J. Cancer95(11), 1459–1466 (2006).
- Brown DR, Shew ML, Quadadri B et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J. Invest. Dermatol.191, 182–192 (2005).
- Burd EM. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev.16, 1–17 (2003).
- Zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology184, 9–13 (1991).
- Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer2(5), 342–350 (2002).
- Bosch FX, Muñoz N. The viral etiology of cervical cancer. Virus Res.89, 183–190 (2002).
- Muñoz N, Bosch FX, De Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med.348, 518–527 (2003).
- Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol. Rev.10, 122 (1988).
- Wilson JD, Brown CB, Walker PP. Factors involved in clearance of genital warts. Int. J. STD AIDS12, 789–792 (2001).
- de Villiers E-M, Fauquet C, Broker TR, Bernard H-U, Zur Hausen H. Classification of papillomaviruses. Virology324, 17–27 (2004).
- Opalka D, Lachman CE, MacMullen SA et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin. Diagn. Lab. Immunol.10, 108–115 (2003).
- Stanley M, Lowry DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine24(S3), 106–111 (2006).
- Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med.347, 1645–1651 (2002).
- Villa LL, Ault K, Giuliano et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, 18. Vaccine24, 5571–5583 (2006).
- Villa LL, Costa RLR, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol.6, 271–278 (2005).
- Harper DM, France EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367, 1247–1255 (2006).
- Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet364, 1757–1765 (2004).